{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:38:38Z","timestamp":1793234318235,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The development of Bruton Tyrosine Kinase inhibitors (BTKis) has revolutionized the management of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). However, increased infection rates have been reported in patients receiving BTKis in multiple clinical trials. This study aimed to evaluate the risk of infections associated with BTKis compared to other therapeutic regimens in CLL\/SLL patients. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted. We included trials comparing BTKi-containing regimens (e.g., BTKi alone or combined with anti-CD20 or venetoclax) to other therapeutic regimens, as well as studies comparing different BTKis or BTKi combinations. Primary outcomes were the risk of any infection and grade 3\u20134 infections. Secondary outcomes included pneumonia, sepsis, septic shock, COVID-19, fungal infections, fatal infections, bacteremia, and febrile neutropenia. Pooled risk ratios (RR) with 95% confidence intervals (CIs) were estimated using fixed or random effects models based on heterogeneity. Eighteen trials encompassing 8,324 patients were included. BTKi-containing regimens, either as monotherapy or combined with anti-CD20 or venetoclax, were not associated with a significantly increased risk of any infection compared to other regimens [BTKi\u2009+\u2009anti-CD20 or venetoclax: RR 0.93 (95% CI: 0.79\u20131.09, I<jats:sup>2<\/jats:sup>\u2009=\u200946%), 3 trials; BTKi monotherapy: RR 1.12 (95% CI: 0.94\u20131.34, I<jats:sup>2<\/jats:sup>\u2009=\u200973%), 3 trials]. Similarly, BTKi monotherapy was not associated with an increased risk of grade 3\u20134 infections [RR 1.05 (95% CI: 0.76\u20131.44, I<jats:sup>2<\/jats:sup>\u2009=\u200961%), 5 trials]. The risk of sepsis was not significantly increased with BTKi regimens [BTKi\u2009+\u2009anti-CD20: RR 0.48 (95% CI: 0.12\u20131.84, I<jats:sup>2<\/jats:sup>\u2009=\u200969%), 4 trials; BTKi monotherapy: RR 0.50 (95% CI: 0.25\u20131.01, I<jats:sup>2<\/jats:sup>\u2009=\u20090%), 5 trials]. However, pneumonia risk was increased in the BTKi\u2009+\u2009anti-CD20 vs other regimens, [RR 2.18; 95% CI 1.29\u20133.70; I<jats:sup>2<\/jats:sup>\u2009=\u20093%, 4 trials]. The risk of febrile neutropenia was reduced in trials comparing BTKi-containing regimens to other therapies. BTKi-containing regimens were not associated with an increased risk of overall infections or grade 3\u20134 infections compared to other regimens. However, an elevated risk of pneumonia was observed with BTKi combinations, highlighting the need for careful consideration when selecting treatment regimens for CLL\/SLL patients.<\/jats:p>","DOI":"10.1007\/s00277-025-06502-y","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T14:06:55Z","timestamp":1753452415000},"page":"3903-3915","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Infectious complications in CLL\/SLL patients receiving Bruton's Tyrosine Kinase inhibitors \u2013 systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"104","author":[{"given":"Shira","family":"Buchrits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gal","family":"Trieman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odil","family":"Giladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liron","family":"Hofstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Gurion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galit","family":"Granot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Shacham-Abulafia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Gafter-Gvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"6502_CR1","doi-asserted-by":"publisher","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Xiao W (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","DOI":"10.1038\/s41375-022-01620-2"},{"key":"6502_CR2","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive man-agement of CLL. Blood 131:2745\u20132760","journal-title":"Blood"},{"key":"6502_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","volume":"35","author":"T Wen","year":"2021","unstructured":"Wen T, Wang J, Shi Y, Qian H, Liu P (2021) Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: Drug development advances. Leukemia 35:312\u2013332","journal-title":"Leukemia"},{"key":"6502_CR4","doi-asserted-by":"publisher","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373(25):2425\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1509388","DOI":"10.1056\/NEJMoa1509388"},{"key":"6502_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre D, Tam CS, Mulligan SP, Jaeger U et al (2014) Ibrutinib versus ofa-tumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213\u2013223","journal-title":"N Engl J Med"},{"issue":"31","key":"6502_CR6","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O\u2019Brien S, Yenerel MN, Ill\u00e9s A, Kay N, Garcia-Marco JA, Mato A, Pinilla-Ibarz J, Seymour JF, Lepretre S, Stilgenbauer S, Robak T, Rothbaum W, Izumi R, Hamdy A, Patel P, Higgins K, Sohoni S, Jurczak W (2021) Acalabrutinib versus Ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 39(31):3441\u20133452. https:\/\/doi.org\/10.1200\/JCO.21.01210","journal-title":"J Clin Oncol"},{"issue":"4","key":"6502_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Ka\u017amierczak M, Lamanna N, O\u2019Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MD, Fu L, Li J, Wu K, Cohen A, Shadman M (2023) Zanubrutinib or Ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 388(4):319\u2013332. https:\/\/doi.org\/10.1056\/NEJMoa2211582","journal-title":"N Engl J Med"},{"key":"6502_CR8","unstructured":"Mato AR, Davids MS, Fraser G et al (2024) Pirtobrutinib vs investigator\u2019s choice of idelalisib plus rituximab or bendamustine plus rituximab in relapsed\/refractory CLL\/SLL: primary analysis of the phase 3 BRUIN-CLL-321 trial. Presented at: 65th American Society of Hematology (ASH) Annual Meeting, San Diego, CA. Abstract #123456"},{"issue":"10","key":"6502_CR9","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","volume":"18","author":"S O'Brien","year":"2018","unstructured":"O\u2019Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R (2018) Safety analysis of four randomized controlled studies of Ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 18(10):648-657.e15. https:\/\/doi.org\/10.1016\/j.clml.2018.06.016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"6502_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","volume":"1","author":"KJ Maddocks","year":"2015","unstructured":"Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA (2015) Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol 1(1):80\u201387. https:\/\/doi.org\/10.1001\/jamaoncol.2014.218","journal-title":"JAMA Oncol"},{"issue":"4","key":"6502_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ejh.13020","volume":"100","author":"BF Tillman","year":"2018","unstructured":"Tillman BF, Pauff JM, Satyanarayana G, Talbott M, Warner JL (2018) Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur J Haematol 100(4):325\u2013334. https:\/\/doi.org\/10.1111\/ejh.13020","journal-title":"Eur J Haematol"},{"key":"6502_CR12","unstructured":"Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. https:\/\/handbook-5-1.cochrane.org. Accessed 15 July 2025"},{"issue":"8","key":"6502_CR13","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, \u0160imkovi\u010d M, Shadman M, \u00d6sterborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trn\u011bn\u00fd M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P (2022) Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 23(8):1031\u20131043. https:\/\/doi.org\/10.1016\/S1470-2045(22)00293-5","journal-title":"Lancet Oncol."},{"key":"6502_CR14","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G et al (2020) Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial. Lancet 395:1278\u20131291","journal-title":"Lancet"},{"key":"6502_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/hon.54_2629","volume":"37","author":"P Ghia","year":"2019","unstructured":"Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, Kaplan P, Kraychok I, Illes A, De La Serna J et al (2019) Acalabrutinib vs Rituximab plus Idelalisib (IdR) or Bendamustine (BR) by investigator choice in relapsed\/refractory (RR) chronic lymphocytic leukemia: Phase 3 ASCEND study. Hematol Oncol 37:86\u201387","journal-title":"Hematol Oncol"},{"issue":"5","key":"6502_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","volume":"24","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, Walewska R, Furtado M, Preston G, Neilson JR, Pemberton N, Sidra G, Morley N, Cwynarski K, Schuh A, Forconi F, Elmusharaf N, Paneesha S, Fox CP, Howard DR, Hockaday A, Brown JM, Cairns DA, Jackson S, Greatorex N, Webster N, Shingles J, Dalal S, Patten PEM, Allsup D, Rawstron A, Munir T (2023) Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 24(5):535\u2013552. https:\/\/doi.org\/10.1016\/S1470-2045(23)00144-4","journal-title":"Lancet Oncol"},{"issue":"6","key":"6502_CR17","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","volume":"25","author":"M F\u00fcrstenau","year":"2024","unstructured":"F\u00fcrstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindstr\u00f6m V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, N\u00f6sslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, D\u00fcrig J, Stehle A, V\u00f6hringer M, B\u00f6ttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Br\u00fcggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst B (2024) First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 25(6):744\u2013759. https:\/\/doi.org\/10.1016\/S1470-2045(24)00196-7","journal-title":"Lancet Oncol"},{"issue":"12","key":"6502_CR18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","volume":"24","author":"CU Niemann","year":"2023","unstructured":"Niemann CU, Munir T, Moreno C, Owen C, Follows GA, Benjamini O, Janssens A, Levin MD, Robak T, Simkovic M, Voloshin S, Vorobyev V, Yagci M, Ysebaert L, Qi K, Qi Q, Sinet P, Parisi L, Srinivasan S, Schuier N, Baeten K, Howes A, Caces DB, Kater AP (2023) Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 24(12):1423\u20131433. https:\/\/doi.org\/10.1016\/S1470-2045(23)00452-7","journal-title":"Lancet Oncol"},{"issue":"4","key":"6502_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","volume":"390","author":"T Munir","year":"2024","unstructured":"Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, Paneesha S, Fox CP, Eyre TA, Forconi F, Elmusharaf N, Kennedy B, Gribben J, Pemberton N, Sheehy O, Preston G, Schuh A, Walewska R, Duley L, Howard D, Hockaday A, Jackson S, Greatorex N, Girvan S, Bell S, Brown JM, Webster N, Dalal S, de Tute R, Rawstron A, Patten PEM, Hillmen P, National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup (2024) Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med 390(4):326\u2013337. https:\/\/doi.org\/10.1056\/NEJMoa2310063","journal-title":"N Engl J Med"},{"issue":"26","key":"6502_CR20","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC (2018) Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 379(26):2517\u20132528. https:\/\/doi.org\/10.1056\/NEJMoa1812836","journal-title":"N Engl J Med"},{"issue":"10","key":"6502_CR21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","volume":"133","author":"JA Burger","year":"2019","unstructured":"Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O\u2019Brien S, Wierda WG, Ferrajoli A, Keating MJ (2019) Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 133(10):1011\u20131019. https:\/\/doi.org\/10.1182\/blood-2018-10-879429","journal-title":"Blood"},{"issue":"4","key":"6502_CR22","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3026(20)30433-6","volume":"8","author":"JP Sharman","year":"2021","unstructured":"Sharman JP, Brander DM, Mato AR, Ghosh N, Schuster SJ, Kambhampati S, Burke JM, Lansigan F, Schreeder MT, Lunin SD, Zweibach A, Shtivelband M, Travis PM, Chandler JC, Kolibaba KS, Sportelli P, Miskin HP, Weiss MS, Flinn IW (2021) Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. Lancet Haematol. 8(4):e254\u2013e266. https:\/\/doi.org\/10.1016\/S2352-3026(20)30433-6","journal-title":"Lancet Haematol."},{"key":"6502_CR23","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","volume":"107","author":"C Moreno","year":"2022","unstructured":"Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Novak J, Strugov V, Gill D et al (2022) First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: Final analysis of the randomized, phase 3 iLLUMINATE trial. Haematologica 107:2108","journal-title":"Haematologica"},{"issue":"5","key":"6502_CR24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, Hanson CA, O\u2019Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M (2019) Ibrutinib-Rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 381(5):432\u2013443. https:\/\/doi.org\/10.1056\/NEJMoa1817073","journal-title":"N Engl J Med"},{"issue":"2","key":"6502_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","volume":"17","author":"A Chanan-Khan","year":"2016","unstructured":"Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M, HELIOS investigators (2016) Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 17(2):200\u2013211. https:\/\/doi.org\/10.1016\/S1470-2045(15)00465-9","journal-title":"Lancet Oncol."},{"issue":"21","key":"6502_CR26","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMc2503839","volume":"392","author":"M Mohty","year":"2025","unstructured":"Mohty M, Kharfan-Dabaja MA (2025) Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med 392(21):2180\u20132181. https:\/\/doi.org\/10.1056\/NEJMc2503839","journal-title":"N Engl J Med"},{"issue":"7","key":"6502_CR27","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, K\u00f6ppler H, Kiehl M, S\u00f6kler M, Schlag R, Vehling-Kaiser U, K\u00f6chling G, Pl\u00f6ger C, Gregor M, Plesner T, Trneny M, Fischer K, D\u00f6hner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, B\u00f6ttcher S, Hallek M, International group of investigators, German CLL Study Group (GCLLSG) (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 17(7):928\u2013942. https:\/\/doi.org\/10.1016\/S1470-2045(16)30051-1","journal-title":"Lancet Oncol"},{"key":"6502_CR28","doi-asserted-by":"publisher","first-page":"101180","DOI":"10.1016\/j.blre.2024.101180","volume":"65","author":"M Mikulska","year":"2024","unstructured":"Mikulska M, Oltolini C, Zappulo E, Bartoletti M, Frustaci AM, Visentin A, Vitale C, Mauro FR (2024) Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines. Blood Rev 65:101180. https:\/\/doi.org\/10.1016\/j.blre.2024.101180","journal-title":"Blood Rev"},{"key":"6502_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1182\/blood.V128.22.233.233","volume":"128","author":"SM O\u2019Brien","year":"2016","unstructured":"O\u2019Brien SM, Furman RR, Coutre SE (2016) Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic leukemia. Blood 128:233","journal-title":"Blood"},{"issue":"10","key":"6502_CR30","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3324\/haematol.2017.164103","volume":"102","author":"I de Weerdt","year":"2017","unstructured":"de Weerdt I, Koopmans SM, Kater AP, van Gelder M (2017) Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica 102(10):1629\u20131639. https:\/\/doi.org\/10.3324\/haematol.2017.164103","journal-title":"Haematologica"},{"key":"6502_CR31","doi-asserted-by":"publisher","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, Gregor M, Cymbalista F, Buske C, Hillmen P, Hallek M, Mey U; ESMO Guidelines Committee (2021) Electronic address: clinicalguidelines@esmo.org. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(1):23\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.019","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"6502_CR32","doi-asserted-by":"publisher","unstructured":"Ghosh N, Manzoor BS, Fakhri B, Emechebe N, Alhasani H, Skarbnik A, Jawaid D, Shadman M (2024) Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.19613","DOI":"10.1111\/bjh.19613"},{"issue":"12","key":"6502_CR33","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP (2018) Venetoclax-Rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 378(12):1107\u20131120. https:\/\/doi.org\/10.1056\/NEJMoa1713976","journal-title":"N Engl J Med"},{"key":"6502_CR34","unstructured":"ClinicalTrials.gov. Ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic. leukaemia (CLL) (CLL17). [Cited 2023 Oct 2]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04608318"},{"issue":"33","key":"6502_CR35","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.2217\/fon-2022-0456","volume":"18","author":"CE Ryan","year":"2022","unstructured":"Ryan CE, Davids MS, Hermann R, Shahkarami M, Biondo J, Abhyankar S, Alhasani H, Sharman JP, Mato AR, Roeker LE (2022) MAJIC: a phase III trial of acalabrutinib\u00a0+\u00a0venetoclax versus venetoclax\u00a0+\u00a0obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol 18(33):3689\u20133699. https:\/\/doi.org\/10.2217\/fon-2022-0456","journal-title":"Future Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06502-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06502-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06502-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T07:48:54Z","timestamp":1757663334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06502-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6502"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06502-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}